Sinopharm Group Co Ltd
HKEX:1099
Sinopharm Group Co Ltd
HKEX:1099
Price:
20.6
HKD
-1.67%
Market Cap:
64.3B
HKD
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Sinopharm Group Co Ltd
20.6
-0.35 (-1.67%)
| 52 Week Range |
16.06
23.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Sinopharm Group Co Ltd
Balance Sheet
Balance Sheet Decomposition
Sinopharm Group Co Ltd
Sinopharm Group Co Ltd
| Current Assets | 372.2B |
| Cash & Short-Term Investments | 34.4B |
| Receivables | 241.5B |
| Other Current Assets | 96.3B |
| Non-Current Assets | 45.5B |
| Long-Term Investments | 10.6B |
| PP&E | 19.7B |
| Intangibles | 10.1B |
| Other Non-Current Assets | 5.1B |
| Current Liabilities | 281.3B |
| Accounts Payable | 156.6B |
| Accrued Liabilities | 35.2B |
| Other Current Liabilities | 89.5B |
| Non-Current Liabilities | 66.8B |
| Long-Term Debt | 18.5B |
| Other Non-Current Liabilities | 48.2B |
Balance Sheet
Sinopharm Group Co Ltd
Sinopharm Group Co Ltd
Currency: CNY
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
15 232
|
19 966
|
25 573
|
32 241
|
40 299
|
39 192
|
50 178
|
43 529
|
55 222
|
63 809
|
|
| Cash |
15 232
|
19 966
|
25 573
|
32 241
|
40 299
|
39 192
|
50 178
|
43 529
|
55 222
|
63 809
|
|
| Short-Term Investments |
1
|
2
|
5
|
1
|
41
|
0
|
39
|
12
|
106
|
5
|
|
| Total Receivables |
67 071
|
66 595
|
72 781
|
84 914
|
110 364
|
126 563
|
149 448
|
176 273
|
175 733
|
189 797
|
|
| Accounts Receivables |
61 825
|
58 346
|
59 759
|
68 557
|
96 610
|
109 497
|
134 404
|
159 409
|
153 283
|
165 966
|
|
| Other Receivables |
5 246
|
8 249
|
13 022
|
16 357
|
13 754
|
17 066
|
15 044
|
16 864
|
22 450
|
23 831
|
|
| Inventory |
20 309
|
22 553
|
25 760
|
30 273
|
35 389
|
42 594
|
47 085
|
51 500
|
60 926
|
60 028
|
|
| Other Current Assets |
7 660
|
8 784
|
8 641
|
15 343
|
18 562
|
21 650
|
20 859
|
19 608
|
27 420
|
23 197
|
|
| Total Current Assets |
110 272
|
117 900
|
132 760
|
162 771
|
204 655
|
230 000
|
267 610
|
290 922
|
319 406
|
336 835
|
|
| PP&E Net |
7 102
|
7 642
|
6 752
|
9 008
|
11 025
|
18 063
|
18 896
|
19 408
|
19 647
|
19 898
|
|
| PP&E Gross |
7 102
|
7 642
|
6 752
|
9 008
|
11 025
|
18 063
|
18 896
|
19 408
|
19 647
|
19 898
|
|
| Accumulated Depreciation |
2 600
|
3 243
|
3 130
|
4 206
|
5 183
|
6 205
|
7 404
|
8 833
|
14 845
|
16 457
|
|
| Intangible Assets |
2 624
|
2 723
|
2 448
|
2 554
|
2 577
|
3 325
|
3 442
|
3 193
|
3 015
|
3 010
|
|
| Goodwill |
3 724
|
4 000
|
3 835
|
4 699
|
4 899
|
5 664
|
7 287
|
7 199
|
7 156
|
7 186
|
|
| Note Receivable |
0
|
1 550
|
3 788
|
14
|
10
|
18
|
34
|
12
|
6
|
6
|
|
| Long-Term Investments |
1 640
|
1 850
|
4 200
|
6 911
|
7 649
|
8 520
|
9 107
|
9 773
|
10 379
|
11 052
|
|
| Other Long-Term Assets |
3 293
|
3 765
|
3 928
|
4 735
|
4 956
|
4 299
|
4 861
|
4 906
|
5 166
|
5 408
|
|
| Other Assets |
3 724
|
4 000
|
3 835
|
4 699
|
4 899
|
5 664
|
7 287
|
7 199
|
7 156
|
7 186
|
|
| Total Assets |
128 656
N/A
|
139 430
+8%
|
157 712
+13%
|
190 693
+21%
|
235 771
+24%
|
269 888
+14%
|
311 237
+15%
|
335 412
+8%
|
364 775
+9%
|
383 395
+5%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
54 724
|
59 563
|
66 746
|
72 492
|
83 683
|
100 334
|
112 632
|
128 431
|
137 085
|
146 632
|
|
| Accrued Liabilities |
1 692
|
2 130
|
2 654
|
4 057
|
4 476
|
5 404
|
7 760
|
8 354
|
9 571
|
8 832
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
25 233
|
28 355
|
22 363
|
31 649
|
50 085
|
43 669
|
56 365
|
56 700
|
54 633
|
56 527
|
|
| Other Current Liabilities |
4 372
|
5 573
|
7 975
|
16 386
|
21 830
|
29 017
|
27 220
|
25 821
|
33 673
|
29 499
|
|
| Total Current Liabilities |
86 020
|
95 622
|
99 737
|
124 583
|
160 074
|
178 425
|
203 977
|
219 307
|
234 963
|
241 491
|
|
| Long-Term Debt |
4 223
|
758
|
11 205
|
5 594
|
5 019
|
11 470
|
12 162
|
11 669
|
14 957
|
17 255
|
|
| Deferred Income Tax |
633
|
693
|
601
|
847
|
865
|
1 099
|
1 112
|
1 023
|
937
|
788
|
|
| Minority Interest |
8 908
|
10 768
|
12 722
|
19 646
|
25 454
|
29 517
|
33 588
|
37 768
|
42 001
|
45 737
|
|
| Other Liabilities |
1 491
|
1 478
|
1 636
|
1 722
|
1 537
|
1 955
|
4 039
|
3 760
|
3 849
|
3 542
|
|
| Total Liabilities |
101 274
N/A
|
109 319
+8%
|
125 901
+15%
|
152 392
+21%
|
192 949
+27%
|
222 466
+15%
|
254 878
+15%
|
273 526
+7%
|
296 707
+8%
|
308 813
+4%
|
|
| Equity | |||||||||||
| Common Stock |
2 767
|
2 767
|
2 767
|
2 767
|
2 972
|
2 972
|
3 121
|
3 121
|
3 121
|
3 121
|
|
| Retained Earnings |
6 521
|
9 232
|
10 936
|
17 441
|
18 615
|
23 212
|
28 574
|
34 107
|
40 293
|
71 465
|
|
| Additional Paid In Capital |
18 077
|
18 077
|
18 077
|
18 077
|
21 223
|
21 223
|
24 641
|
24 641
|
24 641
|
0
|
|
| Unrealized Security Profit/Loss |
17
|
34
|
31
|
17
|
12
|
16
|
23
|
20
|
17
|
0
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
4
|
4
|
|
| Total Equity |
27 382
N/A
|
30 110
+10%
|
31 811
+6%
|
38 301
+20%
|
42 822
+12%
|
47 422
+11%
|
56 359
+19%
|
61 886
+10%
|
68 069
+10%
|
74 582
+10%
|
|
| Total Liabilities & Equity |
128 656
N/A
|
139 430
+8%
|
157 712
+13%
|
190 693
+21%
|
235 771
+24%
|
269 888
+14%
|
311 237
+15%
|
335 412
+8%
|
364 775
+9%
|
383 395
+5%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
2 767
|
2 767
|
2 767
|
2 767
|
2 972
|
2 972
|
3 121
|
3 121
|
3 121
|
3 121
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
